JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 20, 2008; DOI: 10.1124/jpet.107.135327


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.107.135327v1
325/2/466    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yue, T.-L.
Right arrow Articles by Willette, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yue, T.-L.
Right arrow Articles by Willette, R. N.


Received for publication December 18, 2007.
Revised January 30, 2008.
Accepted for publication February 15, 2008.

In Vivo Activation of Peroxisome Proliferator-Activated Receptor-{delta} Protects the Heart from Ischemia/Reperfusion Injury in Zucker Fatty Rats

Tian-Li Yue 1*, Sandhya S. Nerurkar 2, Weike Bao 2, Beat M. Jucker 2, Lea Sarov-Blat 2, Klaudia Steplewski 3, Eliot H. Ohlstein 3, Robert N. Willette 3

1 GlaxoSmithKline Pharmaceuticals 2 GlaxoSmithKline 3 GSK

* Address correspondence to: E-mail: tian-li_yue{at}gsk.com

Abstract

Peroxisome proliferator-activated receptor-{delta} (PPAR-{delta}) is a transcription factor that belongs to PPAR family. PPAR-{delta} is abundantly expressed in the heart and its role in the heart is largely unknown. We tested whether pharmacological activation of PPAR-{delta} protects the heart from ischemia/reperfusion (I/R) injury in male Zucker fatty rats, a rodent model of obesity and dyslipidemia. A highly selective PPAR-{delta} agonist, GW0742, was administered for 7 days at 10 mg/kg/day (po, once a day). Ischemic injury was produced by occlusion of the left anterior descending artery for 30 min followed by reperfusion for up to 24 hours. Treatment with GW0742 reduced serum levels of cardiac troponin-I and infarct size by 63% (p<0.01) and 32% (p<0.01), respectively, and improved left ventricular function. Treatment with GW0742 up-regulated gene expression involved in cardiac fatty acid oxidation, increased fat utilization in the heart and reduced serum levels of free fatty acids. The enhanced cardiac expression of IL-6, IL-8, ICAM-1, and MCP-1 induced by I/R were significantly attenuated by GW0742. Treatment with GW0742 also reduced apoptotic cardiomyocytes by 34% and cardiac caspase-3 activity by 61% (both p<0.01 vs. vehicle). GW0742 differentially regulated Bcl-family members, favoring cell survival, and attenuated I/R-induced cardiac mitochondrial damage. In addition, GW0742 treatment augmented the cardiac Akt signaling pathway, as reflected by enhanced p-PDK-1 and p-Akt. The results indicate that activation of PPAR-{delta} protected the heart from I/R injury in Zucker fatty rats, and multiple mechanisms including amelioration of lipotoxicity, anti-inflammation and up-regulation of pro-survival signaling contribute together to the cardioprotection.


Key words: Ischemia,, Lipotoxicity, Reperfusion, apoptosis, inflammation, myocardial infarction





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.